Status:
COMPLETED
Anti Ischemic Effects of Abciximab in Angioplasty and Stenting Patients
Lead Sponsor:
Emory University
Conditions:
Coronary Artery Disease
Eligibility:
All Genders
18-80 years
Brief Summary
AIR STUDY TITLE: Anti-Ischemic effects of Abciximab(Reopro) PATIENT POPULATION: Patients undergoing PCI(an interventional procedure placing a small stent/metallic tube to keep a narrowed artery in y...
Eligibility Criteria
Inclusion
- Have either:
- clinical history of anginal symptoms or positive stress test or
- in stent restenosis
- Have an angiographic \>70% coronary artery stenosis that will be treated with coronary angioplasty or stenting procedure
- For at least four weeks prior to the procedure have been on, no Hmgcoa- reductase inhibitor or a stable statin dose
- negative pregnancy test
- are able to give informed consent
Exclusion
- Coronary intervention within four weeks prior to enrollment.
- Treatment with abciximab antagonist within four weeks.
- treatment with thrombolytic therapy within 48 hours
- MI within 2 months.
- recent infections
- general anesthesia within 3 months.
- renal failure
Key Trial Info
Start Date :
January 1 2003
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 1 2009
Estimated Enrollment :
220 Patients enrolled
Trial Details
Trial ID
NCT00379418
Start Date
January 1 2003
End Date
December 1 2009
Last Update
September 12 2013
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Atlanta VA Medical Center
Atlanta, Georgia, United States, 30033
2
Emory University Hospital
Atlanta, Georgia, United States, 30322